Ghrelin for Chronic Heart Failure: GH Release, Appetite Stimulation, and Direct Cardiac Protection

Ghrelin offers triple benefits for heart failure: GH-mediated cardiac improvement, appetite stimulation to combat cachexia, and direct cardioprotection through cardiac GHS receptors — a unique multi-mechanism treatment.

Nagaya, Noritoshi et al.·Regulatory peptides·2003·Moderate EvidenceReview
RPEP-00851ReviewModerate Evidence2003RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

Ghrelin provides triple-mechanism benefit for heart failure: GH-mediated cardiac improvement, appetite stimulation counteracting cachexia, and direct GHS-R-mediated cardioprotection — addressing three core disease components.

Key Numbers

How They Did This

Review of ghrelin's cardiac, metabolic, and direct cardioprotective effects with application to heart failure therapy.

Why This Research Matters

Heart failure treatments typically target only one mechanism. Ghrelin simultaneously addresses cardiac dysfunction, wasting, and cellular damage — a comprehensive single-agent approach.

The Bigger Picture

Heart failure is a multi-system disease requiring multi-mechanism treatment. Ghrelin's triple action addresses cardiac, metabolic, and cellular components simultaneously.

What This Study Doesn't Tell Us

Review of largely preclinical data. Human heart failure trials with ghrelin were limited at time of publication.

Questions This Raises

  • ?Can chronic ghrelin therapy improve heart failure outcomes?
  • ?Does the appetite increase help or harm in heart failure?
  • ?Which ghrelin mechanism is most important for cardiac benefit?

Trust & Context

Key Stat:
Triple cardiac benefit One peptide addresses three heart failure problems: weak pumping (GH), muscle wasting (appetite), and cell damage (direct protection)
Evidence Grade:
Moderate evidence from a review integrating preclinical cardiac, metabolic, and protective data.
Study Age:
Published in 2003. Ghrelin has been tested in small human heart failure trials with encouraging results.
Original Title:
Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure.
Published In:
Regulatory peptides, 114(2-3), 71-7 (2003)
Database ID:
RPEP-00851

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How can a hunger hormone help heart failure?

Ghrelin does three things: boosts GH to improve heart function, increases appetite to fight the dangerous weight loss of heart failure, and directly protects heart cells from damage. It addresses the complete disease.

Is this being tested in patients?

Small human studies have shown ghrelin improves cardiac function and exercise capacity in heart failure patients. Larger trials are needed.

Read More on RethinkPeptides

Cite This Study

RPEP-00851·https://rethinkpeptides.com/research/RPEP-00851

APA

Nagaya, Noritoshi; Kangawa, Kenji. (2003). Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure.. Regulatory peptides, 114(2-3), 71-7.

MLA

Nagaya, Noritoshi, et al. "Ghrelin, a novel growth hormone-releasing peptide, in the treatment of chronic heart failure.." Regulatory peptides, 2003.

RethinkPeptides

RethinkPeptides Research Database. "Ghrelin, a novel growth hormone-releasing peptide, in the tr..." RPEP-00851. Retrieved from https://rethinkpeptides.com/research/nagaya-2003-ghrelin-a-novel-growth

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.